 Home > Medical News > Medicines Company News > Sino-Cheng Jianhua announced the completion of the first patient administration in China in the Tafasitamab combined with lenalidomide for relapse/refractory DLBCL Phase II registered clinical trials

Sino-Cheng Jianhua announced the completion of the first patient administration in China in the Tafasitamab combined with lenalidomide for relapse/refractory DLBCL Phase II registered clinical trials

 Last Update: 2022-09-21
 Source: Internet
 Author: User

Tags

igf 1 injection

hiv injection treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sino-Cheng Jianhua (HKEx: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) adult patients who are not suitable for autologous stem cell transplantation (ASCT) has completed phase II registered clinical trial (registration number: CTR20221519) in China

Dr.

Tafasitamab is a humanized monoclonal antibody that targets CD19's Fc domain optimization, and has not been approved by the State Drug Administration for any indications

Tafasitamab has received conditional approval from the U.

About tafasitamab

Tafasitamab is a humanized monoclonal antibody

In 2010, MorphoSys acquired the exclusive worldwide right

Tafasitamab contains Xencor's unique XmAb^® engineered Fc domain, which significantly enhances antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP), which mediate the lysis of B-cell tumors through apoptosis and immune effect mechanisms

In the United States, Monjuvi^® (tafasitamab-cxix) is approved by the U.

In Europe, Minjuvi^® (tafasitamab) in combination with lenalidomide, followed by monotherapy for Minjuvi, has been conditionally approved for the treatment of adult patients

As a treatment option for B-cell malignancies, tafasitamab is conducting several clinical studies

Dr.

Tafasitamab is a humanized monoclonal antibody that targets CD19's Fc domain optimization, and has not been approved by the State Drug Administration for any indications

Tafasitamab has received conditional approval from the U.

About tafasitamab

Tafasitamab is a humanized monoclonal antibody

In 2010, MorphoSys acquired the exclusive worldwide right

^®

In the United States, Monjuvi^® (tafasitamab-cxix) is approved by the U.
S.
Food and Drug Administration for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (unspecified) with lenalidomide, including DLBCL, which evolves from low-malignant lymphoma, and patients
who are not suitable for autologous stem cell transplant conditions.
Based on the overall response rate (ORR), this indication was approved expedited
.
Subsequent approval of this indication may depend on the validation of clinical benefit in a validating
trial.

^®

In Europe, Minjuvi^® (tafasitamab) in combination with lenalidomide, followed by monotherapy for Minjuvi, has been conditionally approved for the treatment of adult patients
with relapsed/refractory diffuse large B-cell lymphoma who do not qualify for autologous stem cell transplantation.

^®

As a treatment option for B-cell malignancies, tafasitamab is conducting several clinical studies
of combination drugs.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.